Aktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation
|
|
- Cuthbert Toby Baker
- 5 years ago
- Views:
Transcription
1 Aktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation Dr. med. Petra Langerbeins Universitätsklinik Köln Deutsche CLL Studiengruppe (DCLLSG)
2 OFFENLEGUNG INTERESSENSKONFLIKTE 1. Anstellungsverhältnis oder Führungsposition - 2. Beratungs-, bzw. Gutachtertätigkeit - 3. Patent, Urheberrecht, Verkaufs 4. Besitz von Geschäftsanteilen, Aktien oder Fonds - 5. Honorare Roche, Janssen, Grifols 6. Finanzierung wissenschaftlicher Untersuchungen Janssen 7. Andere Finanzielle Beziehungen Reisekostenunterstützung: Abbvie, Mundipharma, Janssen, Roche 8. Immaterielle Interessenskonflikte -
3 Objektiv messbare biologische Merkmale, die prognostische, diagnostische RISK ASSESSMENT oder prädiktive Aussagekraft haben. BIOMARKER
4 Biomarker Prognostic vs. predictive Treatment and outcome Prognostic marker both Predictive marker Risk of death infections Richter transformation Eichhorst B. ASH Educational. 2016
5 Biomarker TP53-disruptions RESONATE-17: Ibrutinib 420mg/d Stilgenbauer S. et al. Blood Burger JA. et al. Lancet Oncol. 2014
6 Biomarker NOTCH1 mutations NOTCH1 wildtype Median PFS FCR 57 mo. FC 33 mo. NOTCH1 mutated Median PFS FCR 34 mo. FC 34 mo. Stilgenbauer S et al. Blood Pozzo F et al. Leukemia. 2016
7 Biomarker IGHV status FCR300 CLL8-Studie Thompson et al. Blood Fischer K et al. Blood Guo A et al. Oncotarget. 2016
8 Biomarker Clinical stage Binet A Binet B Binet C Binet JL et al. Cancer.1981 Rai KR et al. Blood Pflug & Bahlo et al. Blood. 2014
9 Cumulative Survival Biomarker Duration of remission 6 yrs yrs yrs <1 yr Months Tam CS et al. Blood Fischer K et al. unpublished.
10 Biomarker MRD status Peripheral blood Progression-free survival Bone marrow Overall survival Böttcher S et al. J Clin Oncol Strati P et al. Blood. 2014
11 Biomarker Comorbidity Goede V et al. Haematologica Stauder et al. Annals of Oncol. 2017
12 Biomarker Comorbidity Stauder et al. Annals of Oncol. 2017
13 Biomarker Age Patients 65 years: P < FCR 53.6 months BR 38.5 months Patients > 65 years: P = FCR not reached BR 48.5 months Eichhorst B et al. Lancet Oncol. 2016
14 Multivariates, statistisches Verfahren zur Analyse hierarchisch strukturierter Daten. RISK ASSESSMENT HIERARCHIAL MODELS
15 Hierarchical model FISH Döhner et al. N Engl J of Med. 2000
16 Integrated cytogenetic model NOTCH1, SF3B1, BIRC3 Rossi D et al. Blood. 2013
17 comorbidity IGHV status age clinical stage FISH MRD NOTCH1 duration of remission RISK ASSESSMENT SCORING SYSTEMS
18 Scoring systems MDACC-score / GCLLSG-score Biomarker Score Age [years] < > 65 3 Sex Female 0 Male 1 ß2-microglobulin < ULN x ULN 1 > 2 ULN 2 Rai stage 0-II 0 III-IV 1 Lymphocyte count [10 9 /L] < >50 2 Involved nodal areas Risk group Low 1-3 Intermediate 4-7 High >7 Biomarker Score Age [years] 60 0 > 60 1 Sex Female 0 Male 1 ß2-microglobulin [mg/dl] > ECOG PS 0 0 > 0 1 Thymidine kinase [U] 10 0 > 10 2 IGHV Mutated 0 Unmutated 1 11q Non-deleted 0 Deleted 1 17p Non-deleted 0 Deleted 6 Risk group Low 1-2 Intermediate 3-5 High 6-10 Very high Wierda WG et al. Blood Pflug N and Bahlo J et al. Blood. 2014
19 Scoring systems CLL-IPI International CLL-IPI working group. Lancet Oncol. 2016
20 Scoring systems CLL-IPI Biomarker Score Age [years] 65 0 > 65 1 Stage Rai 0/Binet A 0 ß2-microglobulin [mg/dl] Rai I-IV/Binet B-C > IGHV Mutated 0 Unmutated 1 TP53 No abnormalities 0 Deletion ± mutation 4 CLL-IPI category OS at 5 ys (%) Low risk 93.2 Do not treat Intermediate risk Potential clinical consequence 79.3 Do not treat except symptomatic High risk 63.3 Treatment indicated except asymptomatic Very high risk 23.3 Do not use chemotherapy (use novel agents or treat within a clinical trial) Risk group Low 0-1 Intermediate 2-3 High 4-6 Very high 7-10 International CLL-IPI working group. Lancet Oncol. 2016
21 ???????? RISK ASSESSMENT FIRST LINE TREATMENT
22 Biomarker Guideline recommendations Clinical stage Disease activity Age Comorbidities TP53 / del17p IGHV Duration of remission IWCLL. International Workshop on CLL ESMO. European Society for Medical Oncology NCCN. National Comprehensive Cancer Network
23 Fit, no TP53-disruption ( 65 years) Rituximab plus FC Binet A, B, C Symptomatic Age 65 CIRS 6 No TP53 / del17p IGHV Duration of remission Wendtner CM et al. Onkopedia. 2017
24 Fit, no TP53-disruption (> 65 years) Rituximab plus Bendamustin Binet A, B, C Symptomatic Age > 65 CIRS 6 No TP53 / del17p IGHV Duration of remission Wendtner CM et al. Onkopedia. 2017
25 Fit, no TP53-disruption FLAIR Binet A, B, C Symptomatic Age CIRS 6 No TP53 / del17p IGHV - irrelevant Duration of remission Patient population Treatment-naive CLL Fit R A N D O M I Z E FCR IR ibrutinib + rituximab I ibrutinib IV ibrutinib + venetoclax Collett L et al. Trials. 2017
26 Fit, no TP53-disruption CLL13 trial Clinical Binet A, stage B, C Disease Symptomatic activity Age Comorbidities CIRS 6 TP53 No TP53 / del17p / del17p IGHV - irrelevant Duration of remission Patient population Treatment-naive CLL Fit R A N D O M I Z E FCR/BR* RV rituximab + venetoclax GV GA venetoclax GIV GA ibrutinib + venetoclax
27 Unfit, no TP53-disruption Chlorambucil + CD20-mAb Binet A, B, C Symptomatic Age CIRS > 6 No TP53 / del17p IGHV - irrelevant Duration of remission Wendtner CM et al. Onkopedia. 2017
28 Unfit, no TP53-disruption ( 65 ys) Ibrutinib Binet A, B, C Symptomatic Age 65 CIRS > 6 No TP53 / del17p IGHV - irrelevant Duration of remission Wendtner CM et al. Onkopedia. 2017
29 Unfit, no TP53-disruption illuminate trial Binet A, B, C Symptomatic Age CIRS > 6 No TP53 / del17p IGHV - irrelevant Duration of remission
30 Unfit, no TP53-disruption CLL14 trial Binet A, B, C Symptomatic Age CIRS > 6 No TP53 / del17p IGHV - irrelevant Duration of remission Patient population Treatment-naive CLL Unfit R A N D O M I Z E Obinutuzumab + Chlorambucil Obinutuzumab + Venetoclax Fischer K. et al., Blood 2017
31 Fit, TP53-disruption Ibrutinib Binet A, B, C Symptomatic Age CIRS 6 TP53 / del17p IGHV - irrelevant Duration of remission Wendtner CM et al. Onkopedia. 2017
32 Unfit, TP53-disruption Ibrutinib Binet A, B, C Symptomatic Age CIRS > 6 TP53 / del17p IGHV - irrelevant Duration of remission Wendtner CM et al. Onkopedia. 2017
33 High risk CLL GIVe trial Binet A, B, C Symptomatic Age CIRS TP53 / del17p IGHV - irrelevant Duration of remission Patient population Treatment-naive del17p / TP53 Obinutuzumab Cycle 1-6 Venetoclax Cycle 1-12 Ibrutinib Cycle 1-12 induction consolidation maintenance
34 Biomarker in CLL Summary A variety of prognostic and predictive biomarkers is available. Prognostic scores help to combine multiple biomarkers. TP53 remains the strongest biomarker. For high risk patients (TP53-disruption) ibrutinib is the first choice. CIT remains the standard of care (FCR, BR, CLB + mab). Comorbidity defines fit, unfit and fragile subgroups. Consider ibrutinib in patients with IGHV unmutated CLL. Combination studies will clarify the role of novel drugs compared to CIT.
35 THANK YOU! Deutsche CLL Studiengruppe
Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD
Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline
More informationFCR and BR: When to use, how to use?
FCR and BR: When to use, how to use? Mitchell R. Smith, M.D., Ph.D. Director of Lymphoid Malignancy Program Taussig Cancer Institute Cleveland Clinic, Cleveland, OH DEBATE ISSUE 2013: Which is the optimal
More informationCLL Ireland Information Day Presentation
CLL Ireland Information Day Presentation 5 May 2018 Professor Patrick Thornton Consultant Haematologist, Senior Lecturer RCSI, and Clinical Director Hermitage Medical Clinic Laboratory Chronic Lymphocytic
More informationCLL what do I need to know as an Internist in Taimur Sher MD Associate Professor of Medicine Mayo Clinic
CLL what do I need to know as an Internist in 218 Taimur Sher MD Associate Professor of Medicine Mayo Clinic Case 1 7 y/o white male for yearly medical evaluation Doing well and healthy Past medical history
More informationAdvances in CLL 2016
Advances in CLL 2016 The Geoffrey P. Herzig Memorial Symposium, Louisville, KY Kanti R. Rai, MD Northwell-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Disclosures Member
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationGeorg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria
Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment
More information1. What to test. 2. When to test
Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Impact of CLL biological features on
More informationRaising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division
Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division University of Virginia Cancer Center The Clinical Continuum of CLL Early asymptomatic
More informationMRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients
MRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November
More informationQuando e se è possibile e u/le o0enere una remissione completa
Quando e se è possibile e u/le o0enere una remissione completa 1) Clinical heterogeneity Disease characteris:cs Pa:ent characteris:cs 2) Modern chemoimmunotherpy approaches 3) New mechanism- based treatment
More informationRisikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL. Michael Hallek University of Cologne
Risikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL Michael Hallek University of Cologne 100 90 80 70 60 Substantial progress in CLL therapy in one decade 50 40 complete remissions
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationLEUCEMIA LINFATICA CRONICA
LEUCEMIA LINFATICA CRONICA Gianluca Gaidano SCDU Ematologia Dipartimento di Medicina Traslazionale Università del Piemonte Orientale Novara Outline CLL biology and pathogenesis Prognostication and prediction
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationChronic Lymphocytic Leukemia. Paolo Ghia
Chronic Lymphocytic Leukemia Paolo Ghia Complex Karyotype: a novel predictive marker? Thompson PA et al. Cancer 2015 Complex karyotype superseded del(17p) Anderson MA et al. Blood 2017 Ibrutinib and Idela
More informationCLL treatment algorithm and state of the art
CLL treatment algorithm and state of the art Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Research Bellinzona - Switzerland CLL subgroups
More informationCLL & SLL: Current Management & Treatment. Dr. Peter Anglin
CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood
More informationClinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel
Clinical Overview: MRD in CLL Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel m.ritgen@med2.uni-kiel.de Remission in CLL Clinical criteria (NCI->WHO) Lymphadenopathy Splenomegaly Hepatomegaly
More informationEfficacy of Bendamustine and rituximab in a real-world patient population
Efficacy of Bendamustine and rituximab in a real-world patient population Median follow-up 37,1 months Efficacy of bendamustine and rituximab as first salvage treatment in CLL and indirect comparison with
More informationChronic lymphocytic leukemia. E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015
Chronic lymphocytic leukemia E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015 Disclosures Travelling to ASH: Roche Consulting services: Janssen Questions in CLL: answers
More informationChronische lymphatische Leukämie. Michael Hallek
Chronische lymphatische Leukämie Michael Hallek Themen Wandel der Prognose CLL8 Follow up CLLM1 Neue Substanzen Ibrutinib CAL101 CLL-Therapie 2013 Studien der DCLLSG Cancer 1981 Clinical Stage and Prognosis
More informationASH up-date: Changing the Standard of Care for Patients with. (or: Who to treat with What When?)
ASH up-date: Changing the Standard of Care for Patients with B-cell Chronic Lymphocytic Leukaemia (or: Who to treat with What When?) Dr Anna Schuh, MD, PhD, MRCP, FRCPath Consultant and Senior Lecturer
More informationBackground. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy
Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract
More informationChronic lymphocytic Leukemia
Chronic lymphocytic Leukemia after IwCLL, ICML and EHA 2017 Ann Janssens, MD, PhD Hematology, UZ Leuven Brussels, 14 september 2017 Front line treatment CLL Active or progressive disease No active or progressive
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationESMO Consensus Empfehlungen 2017
ESMO Consensus Empfehlungen 2017 What s old, what s new, what s missing? Jörg Beyer, Klinik für Onkologie Offenlegung Interessenskonflikte 1. Anstellungsverhältnis oder Führungsposition Keine 2. Beratungs-
More informationL approccio terapeu-co. Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro
L approccio terapeu-co Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro DISCLOSURE Nome: Maria Rosaria Cognome: Villa Impiego nell industria farmaceu7ca negli ul7mi 5 anni: NO Interssi
More informationReviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto)
CLL Updated March 2017 by Doreen Ezeife Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) DISCLAIMER: The following
More informationWe Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT
We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT Danielle M. Brander, MD Duke University Division of Hematologic Malignancies & Cell Therapy CLL & Indolent
More informationOptimizing frontline therapy of CLL based on clinical and biological factors
INDIVIDUALIZING THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA Optimizing frontline therapy of CLL based on clinical and biological factors Kirsten Fischer 1 and Michael Hallek 1,2 1 Department I of Internal
More informationImproving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy
New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia
More informationDebate Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy
Debate Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy Steven Coutre, MD Stanford Cancer Institute William G. Wierda, MD, PhD The University
More informationManagement of 17p Deleted CLL Patients in the Era of Targeted Therapy
Management of 17p Deleted CLL Patients in the Era of Targeted Therapy Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November 11,
More informationREAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA.
REAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA Roberta Murru Struttura Complessa Ematologia e Centro Trapianti Presidio Ospedaliero
More informationSequencing of chronic lymphocytic leukemia therapies
CHRONIC LYMPHOCYTIC LEUKEMIA Sequencing of chronic lymphocytic leukemia therapies Jacqueline C. Barrientos CLL Research and Treatment Program, Department of Internal Medicine, Hofstra Northwell School
More informationMolecular Markers to Guide Therapy - Chronic Lymphocytic Leukaemia - Stephan Stilgenbauer Ulm University
Molecular Markers to Guide Therapy - Chronic Lymphocytic Leukaemia - Stephan Stilgenbauer Ulm University Chronic Lymphocytic Leukaemia (CLL) Most common leukaemia in adults Diagnosis straightforward CD19+/CD5+/CD23+
More informationPatient Profile of CLL in 1L: the importance of appropriate therapy
Patient Profile of CLL in 1L: the importance of appropriate therapy Pr Loic YSEBAERT Service d Hématologie Institut Universitaire du cancer de Toulouse-Oncopole Toulouse, FRANCE ysebaert.loic@iuct-oncopole.fr
More informationCLL Biology and Initial Management. Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology
CLL Biology and Initial Management Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology CLL- Epidemiology Most common adult leukemia 25-30% in western world Incidence in US 4.5
More informationChronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances
Chronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances 2017 Master Class Course John C. Byrd, MD D Warren Brown Chair of Leukemia Research Distinguished University
More informationAdvances in the treatment of Chronic Lymphocytic Leukemia
Advances in the treatment of Chronic Lymphocytic Leukemia Lab of B Cell Neoplasia - Division of Experimental Oncology Strategic Research Program on CLL Department of Onco-Hematology Università Vita-Salute
More informationChronic lymphocytic leukemia
Chronic lymphocytic leukemia How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2018 Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA DISCLOSURES I am on
More informationUpdate on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question?
Welcome to Master Class for Oncologists New York, NY May 14, 2010 Session 5: 4:20 PM - 5:00 PM Update on Management of CLL John C. Byrd, MD D Warren Brown Professor of Leukemia Research Professor of Medicine
More informationEmerging Treatments and Evolving Pathways for the Management of Chronic Lymphocytic Leukemia
Emerging Treatments and Evolving Pathways for the Management of Chronic Lymphocytic Leukemia This educational activity is supported by an educational grant from AbbVie Faculty Jennifer R Brown, MD PhD
More informationCLL Brad Kahl, MD Professor of Medicine
CLL 2016 Brad Kahl, MD Professor of Medicine Disclosures Advisory Committee Consulting Agreements Contracted Research Roche Laboratories Inc, Takeda Oncology Bristol-Myers Squibb Company, Celgene Corporation,
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: January, 2017 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team synthesis of currently accepted
More informationThe mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment
INDIVIDUALIZING THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment Gianluca Gaidano 1 and Davide Rossi 2,3 1 Division
More informationManagement of Patients With Relapsed Chronic Lymphocytic Leukemia
Management of Patients With Relapsed Chronic Lymphocytic Leukemia Polina Shindiapina, MD, PhD, and Farrukh T. Awan, MD Abstract The management of chronic lymphocytic leukemia (CLL) has improved significantly
More informationLEUCEMIA LINFATICA CRONICA: TERAPIA DEL PAZIENTE IN RECIDIVA
CORSO TEORICO-PRATICO PER LA GESTIONE OTTIMALE DEI PAZIENTI AFFETTI DA LINFOMA MANTELLARE, LINFOMA FOLLICOLARE E LEUCEMIA LINFATICA CRONICA Torino, 21-23 Maggio 2018 LEUCEMIA LINFATICA CRONICA: TERAPIA
More informationCLL: treatment goals and therapeutic approach
CLL: treatment goals and therapeutic approach Clemens Wendtner Professor of Medicine Secretary of GCLLSG University of Cologne and Director Klinikum Schwabing Academic Teaching Hospital of University of
More informationUPDATES IN CHRONIC LYMPHOCYTIC LEUKEMIA TANYA SIDDIQI, MD
UPDATES IN CHRONIC LYMPHOCYTIC LEUKEMIA TANYA SIDDIQI, MD DISCLOSURE Speaker s bureau: Pharmacyclics, Janssen, Seattle Genetics, Astra Zeneca Consultant: Juno therapeutics, Astra Zeneca, BeiGene, Pharmacyclics
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: June, 2018 Copyright (2018) Alberta Health Services This material is protected by Canadian and other international copyright laws. All rights reserved. This
More informationChronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology 26 (Supplement 5): v78 v84, 2015 doi:10.1093/annonc/mdv303 Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B. Eichhorst 1, T.
More informationChronic lymphocytic leukemia is eradication feasible and worthwhile?
Chronic lymphocytic leukemia is eradication feasible and worthwhile? Gianluca Gaidano, MD, PhD Division of Hematology Department of Clinical and Experimental Medicine Amedeo Avogardo University of Eastern
More informationManagement of Chronic Lymphatic Leukemia Beyond conventional therapy
3 rd Young Hematologists Orientation Program SGPGI Lucknow August 18 th -19 th 218 Management of Chronic Lymphatic Leukemia Beyond conventional therapy Prof. Hari Menon. MD DM Department of Hemato-Oncology
More informationWhat s on the Horizon for Chronic Lymphocytic Leukemia?
What s on the Horizon for Chronic Lymphocytic Leukemia? Matthew S. Davids, MD, MMSc Associate Director Center for Chronic Lymphocytic Leukemia Assistant Professor of Medicine Harvard Medical School Dana
More informationCLL: future therapies. Dr. Nathalie Johnson
CLL: future therapies Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck Outline Treatment of relapsed
More informationHighlights in chronic lymphocytic leukemia
Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic
More informationUNMET NEEDS OF PATIENTS WITH CLL/SLL AND FL. June 6, 2018
UNMET NEEDS OF PATIENTS WITH CLL/SLL AND FL June 6, 2018 0 PRESENTATION OVERVIEW IN CLL/SLL AND FL: Review patient heterogeneity and its connection to unmet needs Explore unmet needs within the CLL/SLL
More informationCLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016
CLL - venetoclax Peter Hillmen peter.hillmen@nhs.net St James s University Hospital Leeds 10 th May 2016 Pathophysiology of CLL: Proliferation vs Apoptosis Proliferation Apoptosis Ki-67 Expression Bcl-2
More informationDNMT- and HDAC-inhibitors globally induce cryptic transcription start sites encoded in long terminal repeats
DNMT- and HDAC-inhibitors globally induce cryptic transcription start sites encoded in long terminal repeats DGHO Jahrestagung, 29.09.-03.10.2017 Stuttgart Germany Michael Daskalakis of Epigenomics and
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 ARZERRA 100 mg, concentrate for solution for infusion B/3 (CIP code: 577 117-9) B/10 (CIP code: 577
More informationPublished Ahead of Print on February 13, 2012 as /JCO J Clin Oncol by American Society of Clinical Oncology
Published Ahead of Print on February 13, 212 as 1.12/JCO.211.36.9348 The latest version is at http://jco.ascopubs.org/cgi/doi/1.12/jco.211.36.9348 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Ibrutinib for treating chronic lymphocytic leukaemia.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Ibrutinib for treating chronic lymphocytic leukaemia Final scope Remit/appraisal objective To appraise the clinical and cost
More information15 th Annual Miami Cancer Meeting
15 th Annual Miami Cancer Meeting CLL and CML Mohamed A. Kharfan-Dabaja, MD, MBA, FACP Director, Blood and Marrow Transplantation and Cellular Therapies Mayo Clinic Jacksonville, FL 15 th Annual Miami
More informationThe International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist. Other Advances in Leukemia/MDS ALL AML MDS
The Oncologist The International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist Peer-Reviewed Journal for the Practicing Oncologist/Hematologist 20 th Anniversary Overview
More informationChronic lymphocytic leukemia
Chronic lymphocytic leukemia Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2017 Disclosures Speaker
More informationWatch and Wait Actualities in the Treatment of Chronic Lymphocytic Leukemia
CLINICAL UPDATE HEMATOLOGY // INTERNAL MEDICINE Watch and Wait Actualities in the Treatment of Chronic Lymphocytic Leukemia Szilárd Bíró 1, István Benedek Jr 1,2, Árpád Bzduch 1, Johanna Sándor-Kéri 1,2,
More informationPROGNOSTICATION IN CLL: PRESENT AND FUTURE
PROGNOSTICATION IN CLL: PRESENT AND FUTURE Gianluca Gaidano, M.D., Ph.D. Division of Hematology Department of Translational Medicine Amedeo Avogadro University of Eastern Piedmont Novara-Italy CLL: Homogeneous
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationDFCR. Dept. of Medical Oncology, Dana-Farber Cancer Institute 2. Dept. of Medical Oncology, Beth Israel Deaconess Medical Center Boston, USA
A Phase IB/II Study of Duvelisib in Combination with FCR (DFCR) For Frontline Therapy for Younger CLL Patients DFCR Matthew S. Davids, MD, MMSc 1, David C. Fisher, MD 1, Svitlana Tyekucheva, PhD 1, Haesook
More informationBosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the BFORE Trial
Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the BFORE Trial Tim H. Brümmendorf, 1 Carlo Gambacorti-Passerini, 2 Michael Deininger, 3 Michael J. Mauro, 4 Charles Chuah,
More informationRecent Advances in the Treatment of Non-Hodgkin s Lymphomas
671 Highlights of the NCCN 18th Annual Conference Recent Advances in the Treatment of Presented by Jeremy S. Abramson, MD, and Andrew D. Zelenetz, MD, PhD Abstract Non-Hodgkin s lymphomas (NHL) represent
More informationCLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, Chronic Lymphocytic Leukemia. Paolo Ghia
CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013 Chronic Lymphocytic Leukemia Paolo Ghia CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013
More informationOutcomes of patients with CLL after discontinuing idelalisib
Outcomes of patients with CLL after discontinuing idelalisib Jacqueline C. Barrientos, Manmeen Kaur, Alexis Mark, Jaewon Chung, Nancy Driscoll, Alison Bender, Kanti R. Rai ASH Annual Meeting Abstracts
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 5 January 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 5 January 2011 CHLORAMINOPHENE 2 mg, capsule B/30 (CIP code: 3369906) Applicant: TECHNI-PHARMA chlorambucil ATC code:
More informationPost-ASH 2015 Chronic Lymphocytic Leukaemia. Anna Schuh Consultant Haematologist Oxford
Post-ASH 2015 Chronic Lymphocytic Leukaemia Anna Schuh Consultant Haematologist Oxford NEWS IN FRONT-LINE Consort Diagram CLL10 Study: FCR VS BR in Front-line 688 CLL patients screened centrally for: immunophenotype
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Apply recent clinical research findings with the newly FDA-approved combination of obinutuzumab and chlorambucil to the management and care of patients with previously
More informationRole of Targeted Therapies in the Management of Chronic Lymphocytic Leukemia: From Clinical Data to Individualized Care Ryan Jacobs, MD
Role of Targeted Therapies in the Management of Chronic Lymphocytic Leukemia: From Clinical Data to Individualized Care Ryan Jacobs, MD Department of Hematology Levine Cancer Institute Carolinas Health
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationChronic Lymphocytic Leukemia: State of the Art
14th Annual INDY Hematology Review March 2017 Chronic Lymphocytic Leukemia: State of the Art Adrian Wiestner, MD/PhD Bethesda, MD awiestner@hotmail.com Disclosures Grant/research support: Pharmacyclics
More informationChronic Lymphocytic Leukemia: State of the Art
14th Annual INDY Hematology Review March 2017 Chronic Lymphocytic Leukemia: State of the Art Adrian Wiestner, MD/PhD Bethesda, MD awiestner@hotmail.com Disclosures Grant/research support: Pharmacyclics
More informationIndustry Perspective: Minimal (Measurable) Residual Disease in Chronic Lymphocytic Leukemia
Industry Perspective: Minimal (Measurable) Residual Disease in Chronic Lymphocytic Leukemia Davy Chiodin with Nadia Ono Regulatory Science Acerta (A Member of the AstraZeneca Group) 09 November 2018 1
More informationCLL: State of the Art 2018
CLL: State of the Art 2018 Dr. Susan O Brien, MD Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center; Medical Director, Sue and Ralph Stern Center for Cancer Clinical Trials
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationCLL13 trial of the GCLLSG/GAIA trial Page 4 of 111
CLL13 trial of the GCLLSG/GAIA trial Page 4 of 111 II. Synopsis Sponsor: Global Principal Investigator and medical contact of the sponsor: Coordinating Physician: Head of the GCLLSG: Participating countries:
More informationRichter syndrome: pathogenesis and management. Clemens Wendtner Professor of Medicine Chief Physician Klinikum Schwabing University of Munich
Richter syndrome: pathogenesis and management Clemens Wendtner Professor of Medicine Chief Physician Klinikum Schwabing University of Munich Conflict of Interest Disclosure I hereby declare the following
More informationReal life data from Polish Adult Leukemia Group (PALG) analysis
ORIGINAL ARTICLE Efficacy and safety of obinutuzumab chlorambucil combination in the frontline treatment of elderly patients with chronic lymphocytic leukemia and comorbidities Real life data from Polish
More informationDr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation
ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI
More informationLymphoma and microenvironment
Lymphoma and microenvironment Valter Gattei, MD Head Clinical and Experimental Oncology Unit IRCCS Aviano (PN) % viable cells CLL cells do need microenvironmental CLL and microenvironment... interactions
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Obinutuzumab (Gazyva) for Chronic Lymphocytic Leukemia January 27, 2015
pan-canadian Oncology Drug Review Final Clinical Guidance Report Obinutuzumab (Gazyva) for Chronic Lymphocytic Leukemia January 27, 2015 DISCLAIMER Not a Substitute for Professional Advice This report
More informationTargeted Oncology Chronic Lymphocytic Leukemia Virtual Tumor Board
Targeted Oncology Chronic Lymphocytic Leukemia Virtual Tumor Board Segment 1 Segment Title: Case 1: An Elderly Patient With Newly Diagnosed High-Risk CLL Segment Description: William Wierda, MD, PhD, and
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationGenomic complexity and arrays in CLL. Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy
Genomic complexity and arrays in CLL Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy Clinical relevance of genomic complexity (GC) in CLL GC has been identified as a critical negative
More informationDefining the New Treatment Paradigm for Patients With Chronic Lymphocytic Leukemia
Defining the New Treatment Paradigm for Patients With Chronic Lymphocytic Leukemia Mollie Moran, CNP The James Cancer Hospital at The Ohio State University Jeffrey Jones, MD/MPH Ohio State University Comprehensive
More informationImportance of minor TP53 mutated clones in the clinic
Importance of minor TP53 mutated clones in the clinic Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Reserach Bellinzona - Switzerland
More informationHeng Li, Wenjie Xiong, Huimin Liu, Shuhua Yi, Zhen Yu, Wei Liu, Rui Lyu, Tingyu Wang, Dehui Zou, Zengjun Li, Lugui Qiu
Original Article Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China Heng Li, Wenjie Xiong, Huimin
More informationBiomarkers in Chronic Lymphocytic Leukemia: the art of synthesis. CLL Immunogenetics. Overview. Anastasia Chatzidimitriou
Biomarkers in Chronic Lymphocytic Leukemia: the art of synthesis CLL Immunogenetics Overview Anastasia Chatzidimitriou Belgrade March 17, 2018 B cells: multiple receptors B cell receptor IG unique signature
More information